Diagnostic tests developer EDX Medical Group plc (AQSE Growth Market:EDX) on Friday announced the launch of TC100, a new early detection blood test for testicular cancer, in the United Kingdom.

The test delivers up to 99% sensitivity and 96% specificity for primary diagnosis, and 100% sensitivity for detecting cancer recurrence post-treatment.

Designed for broad use across ages and ethnicities, TC100 combines proprietary micro-RNA biomarker M371 with three traditional serum biomarkers -- AFP, HCG, and LDH -- analysed through an AI-powered algorithm. The non-invasive blood test can be administered by health professionals and is intended as a diagnostic aid for clinicians.

EDX Medical's test is backed by over 30 clinical studies demonstrating its use in early detection, diagnosis, metastasis assessment and recurrence monitoring of both seminoma and non-seminoma testicular cancer.

There are approximately 2,500 new testicular cancer cases annually in the UK, with 50,000 survivors who may benefit from accurate monitoring. The launch aligns with Testicular Cancer Awareness Month, which promotes early detection to improve survival rates, currently exceeding 90%.

The test will be available to both private and public healthcare providers within weeks.